ES2303768B1 - NEW CRYSTAL FORM OF MOXIFLOXACINO CHLORHYDRATE. - Google Patents
NEW CRYSTAL FORM OF MOXIFLOXACINO CHLORHYDRATE. Download PDFInfo
- Publication number
- ES2303768B1 ES2303768B1 ES200602303A ES200602303A ES2303768B1 ES 2303768 B1 ES2303768 B1 ES 2303768B1 ES 200602303 A ES200602303 A ES 200602303A ES 200602303 A ES200602303 A ES 200602303A ES 2303768 B1 ES2303768 B1 ES 2303768B1
- Authority
- ES
- Spain
- Prior art keywords
- moxifloxacin hydrochloride
- crystalline form
- methanol
- vol
- raw
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 5
- 239000013078 crystal Substances 0.000 claims abstract description 3
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 claims abstract 17
- 238000010586 diagram Methods 0.000 claims description 6
- 238000002329 infrared spectrum Methods 0.000 claims description 5
- 238000002441 X-ray diffraction Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000003701 inert diluent Substances 0.000 claims 1
- SKZIMSDWAIZNDD-WJMOHVQJSA-N 7-[(4as,7as)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrate;hydrochloride Chemical compound O.Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 SKZIMSDWAIZNDD-WJMOHVQJSA-N 0.000 description 22
- 239000003814 drug Substances 0.000 description 5
- 229960003702 moxifloxacin Drugs 0.000 description 5
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- -1 moxifloxacin compound Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Nueva forma cristalina de moxifloxacino clorhidrato.New crystalline form of moxifloxacin hydrochloride
La presente invención se refiere a una nueva forma cristalina estable de moxifloxacino clorhidrato, al procedimiento de su preparación y a su uso en la preparación de composiciones farmacéuticas.The present invention relates to a new stable crystalline form of moxifloxacin hydrochloride, at procedure of its preparation and its use in the preparation of pharmaceutical compositions
Se proporciona un procedimiento que comprende disolver moxifloxacino clorhidrato crudo en una mezcla de metanol/agua mediante calentamiento a la temperatura de reflujo; añadir acetona y se lleva la disolución a una temperatura comprendida entre 40 y 45ºC; enfriar la disolución hasta una temperatura comprendida entre 15 y 25ºC; separar los cristales formados por filtracción; lavar y secar el producto obtenido hasta peso constante.A procedure is provided comprising dissolve raw moxifloxacin hydrochloride in a mixture of methanol / water by heating to reflux temperature; add acetone and the solution is brought to a temperature between 40 and 45 ° C; cool the solution to a temperature between 15 and 25 ° C; separate the crystals formed by filtration; wash and dry the product obtained until constant weight
Description
Nueva forma cristalina de moxifloxacino clorhidrato.New crystalline form of moxifloxacin hydrochloride
La presente invención se refiere a una nueva forma cristalina estable de moxifloxacino clorhidrato, al procedimiento de su preparación y a su uso en la preparación de composiciones farmacéuticas.The present invention relates to a new stable crystalline form of moxifloxacin hydrochloride, at procedure of its preparation and its use in the preparation of pharmaceutical compositions
El moxifloxacino clorhidrato es la denominación común internacional del ácido 1-ciclopropil-6-fluoro-1,4-dihidro-8-metoxi-7-[(4aS,7aS)-octahidro-6H-pirrol[3,4-b]piridin-6-il]-4-oxo-3-quinolin carboxílico clorhidrato de Fórmula (I), de aplicación en medicina y utilizado como agente antibacteriano.Moxifloxacin hydrochloride is the denomination international acid common 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7 - [(4aS, 7aS) -octahydro-6H-pyrrole [3,4-b] pyridin-6-yl] -4-oxo- 3-quinolin carboxylic hydrochloride of Formula (I), for application in medicine and used as an antibacterial agent.
El moxifloxacino racémico fue descrito por primera vez en la patente europea EP 350.733-B y en la solicitud europea EP-A-550.903 se describe específicamente moxifloxacino, producto de configuración (S,S).Racemic moxifloxacin was described by first time in European patent EP 350,733-B and in European application EP-A-550,903 Moxifloxacin, configuration product is specifically described (H.H).
En la patente europea EP-780.390-B se describe un polimorfo del monohidrato de moxifloxacino clorhidrato con un diagrama de difracción de Rayos X característico. Posteriormente, en la solicitud internacional WO 04/091619-A1 se describe una nueva forma cristalina de moxifloxacino clorhidrato anhidro y en la solicitud internacional WO 05/054240-A1 se describen otras dos nuevas formas cristalinas de moxifloxacino clorhidrato.In the European patent EP-780,390-B describes a polymorph of moxifloxacin hydrochloride monohydrate with a Characteristic X-ray diffraction diagram. Subsequently, in International application WO 04/091619-A1 is describes a new crystalline form of moxifloxacin hydrochloride anhydrous and in the international application WO 05/054240-A1 describes two other new ways crystalline moxifloxacin hydrochloride.
La estabilidad de una sustancia farmacéuticamente activa es importante en las composiciones farmacéuticas para determinar el tiempo de conservación del medicamento. Por ello, la sustancia farmacéuticamente activa usada para preparar composiciones farmacéuticas debe ser lo más estable posible para garantizar su estabilidad en almacenamiento de larga duración bajo diversas condiciones ambientales. Ha de tenerse en cuenta que cualquier cambio relativo al estado sólido de una composición farmacéutica, que sea capaz de mejorar su estabilidad física proporciona una ventaja significativa con respecto a formas menos estables del medicamento.The stability of a substance pharmaceutically active is important in the compositions pharmaceuticals to determine the shelf life of medicine. Therefore, the pharmaceutically active substance used to prepare pharmaceutical compositions must be the most stable possible to ensure its long storage stability duration under various environmental conditions. It must be held in note that any change relative to the solid state of a pharmaceutical composition, which is able to improve its stability physics provides a significant advantage over forms Less stable medication.
De este modo, la finalidad de la invención es proporcionar una nueva forma cristalina del compuesto moxifloxacino clorhidrato que tenga propiedades físicas constantes.Thus, the purpose of the invention is provide a new crystalline form of the moxifloxacin compound hydrochloride that has constant physical properties.
La presente invención tiene por objeto proporcionar una nueva forma polimórfica de moxifloxacino clorhidrato estable.The present invention aims at provide a new polymorphic form of moxifloxacin stable hydrochloride
Otro objeto de la presente invención es proporcionar un procedimiento para la preparación de dicha forma polimórfica.Another object of the present invention is provide a procedure for preparing such form polymorphic
Es también objeto de la presente invención proporcionar composiciones farmacéuticas que comprendan la nueva forma polimórfica objeto de la invención.It is also object of the present invention provide pharmaceutical compositions that comprise the new Polymorphic form object of the invention.
La Figura 1 muestra el diagrama de difracción de Rayos X sobre polvo para la nueva forma cristalina objeto de la invención.Figure 1 shows the diffraction diagram of X-rays on powder for the new crystalline form object of the invention.
La Figura 2 muestra el espectro de infrarrojo de la nueva forma cristalina objeto de la invención.Figure 2 shows the infrared spectrum of the new crystalline form object of the invention.
De acuerdo a uno de los objetos de la presente invención, se ha descubierto sorprendentemente una nueva forma cristalina de moxifloxacino clorhidrato estable y adecuada para su utilización como principio activo en composiciones farmacéuticas.According to one of the objects of this invention, a new way has surprisingly been discovered Crystalline moxifloxacin hydrochloride stable and suitable for your use as active ingredient in compositions Pharmaceuticals
La nueva forma cristalina de moxifloxacino clorhidrato, objeto de la invención se estabiliza en forma de sesquihidrato.The new crystalline form of moxifloxacin Hydrochloride, object of the invention is stabilized in the form of sesquihydrate
Por otra parte, la nueva forma cristalina de moxifloxacino clorhidrato, objeto de la invención, se caracteriza por el diagrama de difracción de Rayos X en polvo de la figura 1 teniendo picos característicos a los ángulos 2\theta de 8,1 \pm 0,2, 9,8 \pm 0,2, 15,2 \pm 0,2, 17,7 \pm 0,2 y 22,6 \pm 0,2.Moreover, the new crystalline form of Moxifloxacin hydrochloride, object of the invention, is characterized by the powder X-ray diffraction diagram of Figure 1 having characteristic peaks at 2 \ theta angles of 8.1 \ pm 0.2, 9.8 ± 0.2, 15.2 ± 0.2, 17.7 ± 0.2 and 22.6 ± 0.2.
Asimismo, la nueva forma cristalina de moxifloxacino clorhidrato, objeto de la invención, presenta un espectro infrarrojo que contiene picos característicos mostrados en la tabla 2.Also, the new crystalline form of Moxifloxacin hydrochloride, object of the invention, presents a infrared spectrum that contains characteristic peaks shown in table 2.
De acuerdo con otro aspecto de la invención, se proporciona un procedimiento para la obtención de la nueva forma cristalina de moxifloxacino clorhidrato que comprende las siguientes etapas:In accordance with another aspect of the invention, provides a procedure for obtaining the new form crystalline moxifloxacin hydrochloride comprising the following stages:
- i)i)
- se disuelve moxifloxacino clorhidrato crudo en una mezcla de metanol/agua mediante calentamiento a la temperatura de reflujo;be dissolve raw moxifloxacin hydrochloride in a mixture of methanol / water by heating to the temperature of Reflux;
- ii)ii)
- se añade acetona y se lleva la disolución a una temperatura comprendida entre 40 y 45ºC;be add acetone and bring the solution to a temperature included between 40 and 45 ° C;
- iii)iii)
- a continuación, se enfría la disolución hasta una temperatura comprendida entre 15 y 25ºC;to the solution is then cooled to a temperature between 15 and 25 ° C;
- iv)iv)
- se separan los cristales formados por filtracción;be separate the crystals formed by filtration;
- v)v)
- se lava y se seca el producto obtenido hasta peso constante.be wash and dry the product obtained to constant weight.
El moxifloxacino clorhidrato crudo empleado como producto de partida se obtiene mediante el procedimiento descrito en el ejemplo preparativo que se expone más adelante. La disolución de moxifloxacino clorhidrato crudo se realiza, preferiblemente, en mezclas de metanol/agua 1,5:1 (vol/vol), preferiblemente 1:1 (vol/vol) y se prepara, preferiblemente, empleando hasta 10, preferiblemente entre 7-8, volúmenes de la mezcla metanol/agua por cada unidad de peso de moxifloxacino clorhidrato.The crude moxifloxacin hydrochloride used as Starting product is obtained by the procedure described in the preparative example set out below. Dissolution of crude moxifloxacin hydrochloride is preferably performed in methanol / water mixtures 1.5: 1 (vol / vol), preferably 1: 1 (vol / vol) and is preferably prepared using up to 10, preferably between 7-8, mix volumes methanol / water for each unit of weight of moxifloxacin hydrochloride
Una vez disuelto el moxifloxacino clorhidrato crudo a la temperatura de reflujo, se añade acetona y la disolución se lleva a una temperatura comprendida entre 40ºC y 45ºC y se mantiene en esas condiciones hasta la precipitación del producto y, después, se enfría a una temperatura comprendida entre 15ºC y 25ºC. El enfriamiento se lleva a cabo mediante refrigeración con agua fría y se mantiene durante al menos 1 hora.Once dissolved the moxifloxacin hydrochloride crude at the reflux temperature, acetone is added and the solution it is brought to a temperature between 40 ° C and 45 ° C and is maintains in these conditions until the precipitation of the product and, then, it is cooled to a temperature between 15 ° C and 25 ° C. The cooling is carried out by water cooling cold and kept for at least 1 hour.
El sólido obtenido se separa por filtración y se lava con una mezcla de acetona/metanol/agua. Posteriormente, el sólido húmedo se seca en una estufa con vacío, preferiblemente, a 40ºC hasta peso constante.The solid obtained is filtered off and wash with a mixture of acetone / methanol / water. Subsequently, the wet solid is dried in a vacuum oven, preferably at 40 ° C to constant weight.
La nueva forma cristalina de moxifloxacino clorhidrato obtenida es una forma sesquihidrato estable durante un tiempo prolongado que la hace adecuada para su distribución y almacenamiento. Estas características hacen que la nueva forma polimórfica sea adecuada en el desarrollo de un producto farmacéutico.The new crystalline form of moxifloxacin hydrochloride obtained is a stable sesquihydrate form during a prolonged time that makes it suitable for distribution and storage. These features make the new way polymorphic is appropriate in the development of a product pharmacist.
Todavía otro objeto de la presente invención es proporcionar una composición farmacéutica que comprenda la forma cristalina de moxifloxacino clorhidrato de acuerdo con el primer objeto de la invención junto con uno o más excipientes u otros agentes auxiliares farmacéuticamente aceptables.Still another object of the present invention is provide a pharmaceutical composition that understands the form crystalline moxifloxacin hydrochloride according to the first object of the invention together with one or more excipients or others pharmaceutically acceptable auxiliary agents.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Para el registro del diagrama de difracción de Rayos X en polvo se ha utilizado un difractómetro con las siguientes características:For the registration of the diffraction diagram of X-ray powder has been used a diffractometer with the following features:
XPERT PRO de PANALYTICALXPERT PRO by PANALYTICAL
Tubo de Cobre, a 40KV y 40 mA.Copper tube, at 40KV and 40 mA.
Detector X CELERATORX CELERATOR detector
Barrido angular de 2-45º2-45º angular scan
Monocromador de grafito. Rendija autómaticaGraphite Monochromator Automated slit
Interpretación automática con el software HIGH SCORE.Automatic interpretation with the HIGH software SCORE
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
En la Tabla 1 que sigue se exponen los espacios d interplanares y las intensidades relativas que caracterizan la nueva forma cristalina de moxifloxacino clorhidrato.Table 1 below shows the spaces d interplanares and the relative intensities that characterize the new crystalline form of moxifloxacin hydrochloride.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
El espectro de infrarrojo se obtuvo en KBr utilizando un espectrómetro Perkin Elmer Spectrum One FT-IR. En la tabla 2 que sigue se proporcionan las absorbancias de infrarrojo para la forma cristalina de la invención.The infrared spectrum was obtained in KBr using a Perkin Elmer Spectrum One spectrometer FT-IR Table 2 below provides the infrared absorbances for the crystalline form of the invention.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
El siguiente ejemplo sirve para ilustrar un procedimiento para la preparación de la nueva forma cristalina de moxifloxacino clorhidrato que ha de ser considerado como una realización preferida sin que ello limite el alcance de protección definido por las reivindicaciones adjuntas.The following example serves to illustrate a procedure for the preparation of the new crystalline form of moxifloxacin hydrochloride to be considered as a preferred embodiment without limiting the scope of protection defined by the appended claims.
\newpage\ newpage
Ejemplo 1Example one
10 g de Moxifloxacino clorhidrato crudo se suspenden en una mezcla de 72,5 ml de alcohol metílico/agua (1:1; vol/vol). La mezcla se calienta a reflujo hasta disolución completa del producto y a continuación se adicionan lentamente 72,5 ml de acetona. La disolución resultante se lleva a T = 40-45ºC y se mantiene en esas condiciones hasta la precipitación del producto y después se enfría a T = 15-25ºC durante una hora. Posteriormente, se filtra la suspensión, el sólido se lava con 10 ml de una mezcla de acetona/alcohol metílico/agua (2:1:1; vol/vol/vol) y se seca a 40ºC con vacío hasta peso constante. Se obtienen 6,28 g de Moxifloxacino clorhidrato forma cristalina.10 g of raw Moxifloxacin hydrochloride se Suspend in a mixture of 72.5 ml of methyl alcohol / water (1: 1; vol / vol). The mixture is heated to reflux until complete dissolution. of the product and then 72.5 ml of slowly added acetone. The resulting solution is brought to T = 40-45 ° C and remains in these conditions until the Product precipitation and then cooled to T = 15-25 ° C for one hour. Subsequently, it is filtered the suspension, the solid is washed with 10 ml of a mixture of acetone / methyl alcohol / water (2: 1: 1; vol / vol / vol) and dried at 40 ° C With vacuum to constant weight. 6.28 g of Moxifloxacin are obtained hydrochloride crystalline form.
Claims (11)
- i)i)
- disolver moxifloxacino clorhidrato crudo en una mezcla de metanol/agua mediante calentamiento a la temperatura de reflujo;dissolve moxifloxacin hydrochloride raw in a methanol / water mixture by heating to the reflux temperature;
- ii)ii)
- añadir acetona y llevar la disolución a una temperatura comprendida entre 40 y 45ºC;add acetone and bring the solution at a temperature between 40 and 45 ° C;
- iii)iii)
- enfriar hasta una temperatura comprendida entre 15 y 25ºC;cool to a temperature between 15 and 25 ° C;
- iv)iv)
- separar los cristales formados por filtración;separate the crystals formed by filtration;
- v)v)
- lavar y secar el producto obtenido hasta peso constante.to wash and dry the product obtained to constant weight.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200602303A ES2303768B1 (en) | 2006-09-08 | 2006-09-08 | NEW CRYSTAL FORM OF MOXIFLOXACINO CHLORHYDRATE. |
| PCT/EP2007/059397 WO2008028959A1 (en) | 2006-09-08 | 2007-09-07 | Crystalline form of moxifloxacin hydrochloride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200602303A ES2303768B1 (en) | 2006-09-08 | 2006-09-08 | NEW CRYSTAL FORM OF MOXIFLOXACINO CHLORHYDRATE. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2303768A1 ES2303768A1 (en) | 2008-08-16 |
| ES2303768B1 true ES2303768B1 (en) | 2009-06-05 |
Family
ID=38963213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200602303A Expired - Fee Related ES2303768B1 (en) | 2006-09-08 | 2006-09-08 | NEW CRYSTAL FORM OF MOXIFLOXACINO CHLORHYDRATE. |
Country Status (2)
| Country | Link |
|---|---|
| ES (1) | ES2303768B1 (en) |
| WO (1) | WO2008028959A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083010A1 (en) * | 2008-01-08 | 2009-07-29 | Chemo Ibérica, S.A. | Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof |
| US20110212990A1 (en) * | 2008-11-06 | 2011-09-01 | Hetero Research Foundation | Novel polymorph of moxifloxacin hydrochloride |
| CN102603738B (en) * | 2012-02-24 | 2013-12-11 | 天津市汉康医药生物技术有限公司 | Stable moxifloxacin hydrochloride compound |
| CN102924449B (en) * | 2012-10-30 | 2015-08-12 | 重庆福安药业集团庆余堂制药有限公司 | Moxifloxacin hydrochloride H crystal form and preparation method thereof and pharmaceutical composition |
| CN103965189B (en) * | 2013-12-30 | 2015-09-09 | 西安万隆制药股份有限公司 | A kind of new moxifloxacin hydrochloride compound |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19546249A1 (en) * | 1995-12-12 | 1997-06-19 | Bayer Ag | New crystal modification of 1-cyclopropyl-7 - ([S, S] -2,8-diazabicyclo [4,3,0] non-8-yl) -6-fluoro-1,4-dihydro-8-methoxy-4 -oxo-3-quinoline carboxylic acid hydrochloride (CDCH), process for its preparation and pharmaceutical preparations containing it |
| EP1562942A1 (en) * | 2002-10-31 | 2005-08-17 | Ranbaxy Laboratories, Ltd. | Amorphous moxifloxacin hydrochloride |
| DE602004022646D1 (en) * | 2003-04-09 | 2009-10-01 | Reddys Lab Ltd Dr | CRYSTALLINE FORM III OF A WATER-FREE MOXIFLOXACINE HYDROCHLORIDE AND A METHOD FOR THE PRODUCTION THEREOF |
| US20060264635A1 (en) * | 2003-08-05 | 2006-11-23 | Chava Satyanarayana | Process for the preparation of moxifloxacin hydrochloride |
| WO2005054240A1 (en) * | 2003-11-20 | 2005-06-16 | Chemi Spa | Polymorphs of 1-cyclopropyl-7-([s,s]-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof |
| WO2006134491A2 (en) * | 2005-06-14 | 2006-12-21 | Aurobindo Pharma Limited | New crystalline form of moxifloxacin hydrochloride and process for its preparation |
| WO2007010555A2 (en) * | 2005-07-15 | 2007-01-25 | Msn Laboratories Limited | Novel crystalline forms of moxifloxacin hydrochloride and process for preparation thereof |
| GB0612422D0 (en) * | 2006-06-23 | 2006-08-02 | Generics Uk Ltd | Novel hydrate form |
-
2006
- 2006-09-08 ES ES200602303A patent/ES2303768B1/en not_active Expired - Fee Related
-
2007
- 2007-09-07 WO PCT/EP2007/059397 patent/WO2008028959A1/en active Application Filing
Non-Patent Citations (1)
| Title |
|---|
| RAVIKUMAR, K. & SRIDHAR, B. "{}Moxifloxacinium chloride-water- methanol (2/1/1), a novel antibacterial agent."{} Acta Crystallographica Section C, 2006, Volumen 62, páginas 0478-0482. Ver páginas 478 y 481. * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2303768A1 (en) | 2008-08-16 |
| WO2008028959A1 (en) | 2008-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2608961T3 (en) | New crystalline form VI of agomelatine, process for its preparation and pharmaceutical compositions containing it | |
| JP2022176961A (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| ES2374922T3 (en) | ARIPIPRAZOL CRYSTAL FORMS PREPARATION PROCEDURES. | |
| ES2353853T3 (en) | HYDROGENOSULFATE SALT OF 2-ACETOXI-5 - ("ALPHA" -CICLOPROPILCARBONIL-2-FLUORBENCIL) -4,5,6,7-TETRAHYDROTIENE [3,2-c] PIRIDINE AND ITS PREPARATION. | |
| ES2206423T3 (en) | NEW GAMMA CRYSTAL FORM OF THE PERINDOPRILE T-BUTIL-AMINE SALT, ITS PREPARATION PROCEDURE, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT. | |
| TW200944508A (en) | Novel solid forms of bendamustine hydrochloride | |
| ES2343204T3 (en) | NEW CRYSTAL FORMS OF IRINOTECAN HYDROCHLORIDE. | |
| ES2610398T3 (en) | Salts of pyrrolopyrimidinone derivatives and process for their preparation | |
| ES2303768B1 (en) | NEW CRYSTAL FORM OF MOXIFLOXACINO CHLORHYDRATE. | |
| ES2238941T3 (en) | ZOLPIDEM HEMITARTRATE SOLVATE. | |
| ES2502740T3 (en) | Condensed heterocyclic derivative salt and crystal thereof | |
| ES2581982T3 (en) | Crystalline form of perindopril arginine salt, repair procedure and pharmaceutical compositions that include it | |
| WO2013028495A1 (en) | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma | |
| TW201936605A (en) | Peptidylarginine deiminase inhibitor and use thereof | |
| CN104803971B (en) | Crystal form alpha of compound A mono benzoate, preparation method thereof and pharmaceutical composition containing crystal form | |
| EP2388248B1 (en) | Methods for the preparation of ivabradine sulfate and form i crystal thereof | |
| ES2564973T3 (en) | Salts by adding risperidone acids and pharmaceutical compositions thereof | |
| ES2911894T3 (en) | New salt and solid state forms of escitalopram | |
| KR100878698B1 (en) | Crystalline hydrate of bepotastine metal salt, method for preparing same and pharmaceutical composition comprising same | |
| ES2291503T3 (en) | PSEUDOPOLIMORFICAS FORMS OF CARVEDILOL. | |
| ES2815924T3 (en) | Highly stable crystalline form D1 of the monoethanolamine salt of eltrombopag | |
| KR20110026311A (en) | Novel salts of entecavir | |
| US20150150868A1 (en) | Aripiprazole-organic acid cocrystal, preparation or composition containing same, and preparation method therefor | |
| ES2928785T3 (en) | edaravone salt | |
| ES2532110T3 (en) | Crystal of a thienopyrimidine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20080816 Kind code of ref document: A1 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20180912 |